Page 50 - Product Testing News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Claritas Announces Letter of Intent to Acquire Exclusive Worldwide Rights to Develop R-107 for PAH Claritas Pharmaceuticals, Inc.April 14, 2021 GMT SAN FRANCISCO and TORONTO, April 14, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or “Claritas”) today announced that it has entered into a binding Letter of Intent (the “LOI”) with Salzman Group, Inc. (a Delaware corporation), Salzman Group, Ltd. (an Israeli corporation), and Salzm...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Oncurious NV Reports Encouraging Data from Phase 1 Dose Escalation Study of TB-403 in ... Oxurion NVApril 12, 2021 GMT Leuven, Belgium, Boston, MA, US, 12 April 2021 – 7.30 AM CET – ONCURIOUS NV, a Belgium-based biotech company focused on developing innovative oncology treatments, today announces that encouraging data from a Phase 1 dose escalation study of TB-403 in pediatric subjects with relapsed or refractory medulloblastoma (MB), was presented at the annual meeting of the American Associat...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Valneva Completes Recruitment for Pivotal Phase 3 Trial of Chikungunya Vaccine Candidate and ... VALNEVAApril 12, 2021 GMT Saint-Herblain (France), April 12, 2021 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced that it has completed recruitment for the pivotal Phase 3 trial, VLA1553-301, of its single-shot chikungunya ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ORIC Pharmaceuticals Presents Posters on Four Programs at the 2021 American Association for ... ORIC PharmaceuticalsApril 12, 2021 GMT SOUTH SAN FRANCISCO and SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of resistance in cancer, presented four preclinical poster presentations at the 2021 American Association for Cancer Research (AACR) virtual annual meeting. ORIC-10...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Medigus: Polyrizon Commenced a Pre-Clinical Study Testing Several Formulations of its Bio-Gel ... Medigus LtdApril 12, 2021 GMT OMER, Israel, April 12, 2021 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions and innovative internet technologies, today announced that Polyrizon Ltd. (which Medigus owns 33.24% of its share capital), a private company engaged in developing highly differentiated biological gels for the purpose of protecting patient...